WA
BIVV

WestEnd Advisors’s Bioverativ Inc. Common Stock BIVV Stock Holding History

WestEnd Advisors’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10
Closed -$545 – 37
2017
Q1 		$545 Buy
+10
New +$493 ﹤0.01% 37

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VH
ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

WestEnd Advisors's BIVV Position: Q2 2017 in Review

WestEnd Advisors sold out of Bioverativ Inc. Common Stock (BIVV) in Q2 2017, closing a stake of 10 shares — an estimated $545 sold.

WestEnd Advisors first reported a position in BIVV in Q1 2017 and held it in 1 quarter. The position peaked at $545 in Q1 2017. 452 funds tracked by Wall St. Rank hold BIVV as of Q2 2017.

  • WestEnd Advisors reported no remaining Bioverativ Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • WestEnd Advisors sold 10 Bioverativ Inc. Common Stock shares in Q2 2017, an estimated $545.
  • WestEnd Advisors first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • WestEnd Advisors's Bioverativ Inc. Common Stock position peaked at $545 in Q1 2017.
  • 452 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q2 2017.

Based on WestEnd Advisors's 13F filing for Q2 2017, filed 9 Aug 2017.